Company Overview and News
March 2 (Reuters) - Below are company-related news and stories from French and Benelux media which could have an impact on the region’s markets or individual stocks.
Best known for being the world’s first to introduce the chemical leasing model for waste water treatment in 2015, MAS Active Linea Intimo has now signed on with JAT Holdings for a first of its kind chemical leasing deal that will see JAT teams providing a paint service instead of simply selling a product.
FT. LAUDERDALE, FL / ACCESSWIRE / September 25, 2017 / Paybox Corp. (OTC PINK: PBOX) announced today that it has recently signed multiple new customer contracts through both its direct sales team and banking channel partnership. Paybox Corp provides corporations the Paybox® Cloud Automation suite of Accounts Payable and Accounts Receivable solutions and Integrated Receivable solutions for the banking and financial industry.
Noise pollution has historically received much less public attention than other more visible forms such as air pollution, water pollution, and land pollution. However, times have well and truly changed and the effective tackling of noise pollution has become the need of the hour as it is directly linked to many severe health issues. Noise control systems are expected to become increasingly important in the days ahead; which is why Future Market Insights has drafted a new report 'Noise Control System Market: Global Industry Analysis 2012 - 2016 and Opportunity Assessment 2017 - 2027' that studies the global noise control system market in detail.
Trakm8, the AIM quoted telematics and data provider to the global market place, announces that on 10 August 2017, John Watkins, Executive Chairman of the Company, transferred 338,461 ordinary shares of 1 pence each in the Company ("Ordinary Shares") from being held in his own name to being held by Chase Nominees (the "Transfer").
Trakm8, the AIM quoted telematics and data provider to the global market place, announces that its Annual Report & Accounts for the year ended 31 March 2017 and Notice of its Annual General Meeting ("AGM") have been posted to shareholders and are available online at the Company's website www.trakm8.com/investor-relations.
Trakm8, the AIM quoted telematics and data provider to the global market place, is pleased to announce it has been awarded a five year contract by Calor Gas UK in conjunction with its reseller partner Dakota Integrated Solutions (www.dakotais.co.uk), to supply the RoadHawk 600 integrated camera and telematics solution with tachograph download, driver behaviour and data analytics.
[Calls starts abruptly] …all of our businesses, particularly given the continuing uncertain and inconsistent indicators in our sector, housing transactions, mortgage approvals and consumer confidence. Alan, of course, will cover these numbers in detail. But I would highlight the strong growth in our Contracts and Consumer divisions and good progress in recovering input cost inflation across the Group, especially Travis Perkins merchanting and we've done this through disciplined pricing.
LONDON, July 9 The cladding system used on London's Grenfell Tower would only have met British regulatory standards if the two main materials had passed a key safety test together, according to a Reuters analysis of the building code and data on the materials.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...